Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498816 | 0.95 | AGTR1 (0.51) | AGTR1AGTR2 | |
| SCHEMBL6503001 | 0.95 | AGTR1 (0.49) | PPARGAGTR1AGTR2 | |
| SCHEMBL6501211 | 0.94 | AGTR1 (0.45) | PPARGAGTR1AGTR2 | |
| SCHEMBL8120136 | 0.93 | AGTR1 (0.42) | PPARGAGTR1AGTR2 | |
| SCHEMBL6502356 | 0.92 | AGTR1 (0.45) | PPARGAGTR1AGTR2 | |
| SCHEMBL6490745 | 0.92 | PPARG (0.46) | PPARGAGTR1AGTR2 | |
| SCHEMBL6493722 | 0.92 | AGTR1 (0.52) | AGTR1AGTR2 | |
| SCHEMBL8124160 | 0.92 | AGTR1 (0.41) | PPARGAGTR1AGTR2 | |
| SCHEMBL6493602 | 0.92 | PPARG (0.47) | PPARGAGTR1AGTR2 | |
| SCHEMBL8119948 | 0.91 | AGTR1 (0.43) | PPARGAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864268-B2 | β3 adrenergic receptor agonists | PFIZER INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-6858636-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G. D. SEARLE & CO. | 2004-03-11 | — | — | US | disclosed |
| US-20030212063-A1 | beta3 adrenergic receptor agonists | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6630497-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO | 2003-10-07 | — | — | US | disclosed |
| US-20020038035-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. | 2002-03-28 | — | — | US | disclosed |
| EP-0978515-A2 | 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1994021629-A1 | 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038035-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | AGTR1, AGTR2, REN | PPARG 2171/4885AGTR1 1/4885AGTR2 2/4885 |
| US-20030212063-A1 | beta3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | PPARG 572/4885AGTR1 16/4885AGTR2 27/4885 |
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | AGTR1, AGTR2, REN | PPARG 2171/4885AGTR1 1/4885AGTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.